In this case, the 20 μM concentration GC7, which has been showed had little cytotoxicity against NSCLC cells but could inhibit the eIF5A2 activation, was chosen for further co-treatments with cisplatin. The gene discussed is EIF5A2; the disease is non-small cell lung carcinoma.